Si terrà dal 10 al 13 dicembre 2022 il 64° Congresso annuale ASH, l’evento dedicato all’ematologia più importante a livello internazionale, organizzato dall’American Society of Hematology.
L’evento avrà luogo sia dal vivo all’Ernest N. Morial Convention Center di New Orleans, in Louisiana (USA), sia in modalità virtuale. Il gruppo GIMEMA partecipa con lavori su leucemia linfoblastica acuta a cellule B, leucemia mieloide acuta e qualità di vita.
Il programma dei quattro giorni è composto da numerose sessioni, ed è consultabile, durante il congresso, sul sito dell’Ash oltre che attraverso l’applicazione mobile dell’ASH.
Il gruppo GIMEMA presenta al congresso ASH 2022 i seguenti lavori.
Leucemia mieloide acuta
Presentazione orale:
-
- Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of non Low-Risk Acute Myeloid
Marconi G et al, Blood (2022) 140 (Supplement 1): 1705–1707.
Leggi l’articolo di GIMEMA informazione
- Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of non Low-Risk Acute Myeloid
-
- The addition of venetoclax to induction chemotherapy in no low-risk AML patients: a propensity score-matched analysis of the GIMEMA AML1718 and AML1310 trials
Piciocchi A et al, Blood (2022) 140 (Supplement 1): 137–138.
Leggi l’articolo di GIMEMA informazione
- The addition of venetoclax to induction chemotherapy in no low-risk AML patients: a propensity score-matched analysis of the GIMEMA AML1718 and AML1310 trials
Poster:
-
- The Added Value of Multi‐State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis
Piciocchi A et al, Blood (2022) 140 (Supplement 1): 3192–3193.
Leggi l’articolo di GIMEMA informazione
- The Added Value of Multi‐State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis
Leucemia linfoblastica acuta a cellule B
Poster:
-
-
- GIMEMA ALL2418: Interim Analysis of a Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before any Hematopoietic Stem Cell
Marconi G et al, Blood (2022) 140 (Supplement 1): 6119–6121.
Leggi l’articolo di GIMEMA informazione
- GIMEMA ALL2418: Interim Analysis of a Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before any Hematopoietic Stem Cell
-
Qualità di vita
Presentazione orale:
-
- 10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
Efficace F et al, Blood (2022) 140 (Supplement 1): 1281–1283.
Leggi l’articolo di GIMEMA informazione
- 10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
Poster:
-
- Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study
Caocci G et al, Blood (2022) 140 (Supplement 1): 8119–8121.
Leggi l’articolo di GIMEMA informazione
- Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study
-
- Health-Related Quality of Life and Financial Burden of Ethiopian Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors
Tadesse F et al, Blood (2022) 140 (Supplement 1): 5264–5265.
Leggi l’articolo di GIMEMA informazione
- Health-Related Quality of Life and Financial Burden of Ethiopian Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors